Raymond James & Associates increased its stake in Mednax (NYSE:MD) by 156.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,554 shares of the company’s stock after acquiring an additional 7,660 shares during the period. Raymond James & Associates’ holdings in Mednax were worth $671,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of MD. Delta Capital Management LLC bought a new position in shares of Mednax in the fourth quarter valued at approximately $227,000. Brown Advisory Inc. bought a new position in shares of Mednax in the fourth quarter valued at approximately $231,000. YHB Investment Advisors Inc. bought a new position in shares of Mednax in the fourth quarter valued at approximately $235,000. Shelton Capital Management bought a new position in shares of Mednax in the fourth quarter valued at approximately $245,000. Finally, CHICAGO TRUST Co NA bought a new position in shares of Mednax in the fourth quarter valued at approximately $254,000. Institutional investors and hedge funds own 98.53% of the company’s stock.
MD stock opened at $51.16 on Wednesday. Mednax has a 12 month low of $40.56 and a 12 month high of $63.04. The company has a market cap of $4,786.39, a P/E ratio of 16.24, a price-to-earnings-growth ratio of 1.28 and a beta of 0.23. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.60.
Several research firms have recently issued reports on MD. Stephens set a $62.00 price objective on shares of Mednax and gave the company a “buy” rating in a report on Thursday, February 8th. Jefferies Group set a $50.00 price objective on shares of Mednax and gave the company a “hold” rating in a report on Tuesday, February 6th. Mizuho reiterated a “neutral” rating and issued a $53.00 price objective (up from $49.00) on shares of Mednax in a report on Friday, February 9th. Zacks Investment Research upgraded shares of Mednax from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a report on Tuesday, January 23rd. Finally, BMO Capital Markets increased their price objective on shares of Mednax from $46.00 to $58.00 and gave the company a “market perform” rating in a report on Monday, February 12th. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $55.69.
In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total transaction of $175,050.00. Following the completion of the sale, the insider now directly owns 39,716 shares of the company’s stock, valued at $2,317,428.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.70% of the stock is owned by corporate insiders.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax (NYSE:MD).
Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.